The aim of this study was to evaluate the efficacy and safety of Sofosbuvir/Ledipasvir ± Ribavirin in Malagasy patients with hepatitis C virus genotypes 1 and 2 in real conditions.
This was a retro-prospective, monocentric clinical study, carried out over a period of 3 years from March 1, 2017 to February 28, 2020, in Hepato-gastroenterology department.
A total of 26 patients (M/F: 11/15) with hepatitis C virus genotype 1 (n = 13) and genotype 2 (n = 13), were treated with Sofosbuvir/Ledipasvir without (n = 21) and with (n = 5) Ribavirin for 12 weeks. The mean age was 61.38 ± 7.09. Seventeen (65.4%) patients had cirrhosis. The overall sustained virological response was 96.2% (95% CI = 80.4-99.9%). There was no significant difference between the sustained virological response of genotypes 1 and 2 (92.3% vs. 100%; p = 0.31) and cirrhotic or non-cirrhotic patients (94.1% vs. 100%; p = 0.46). A relapse was observed in one patient (5.9%), cirrhotic, genotype 1b, under Sofosbuvir/Ledipasvir with Ribavirin. Seven patients (26.9%) experienced mild adverse reactions including asthenia (57.1%) and insomnia (42.9%).
Treatment with Sofosbuvir/Ledipasvir ± Ribavirin for infection with hepatitis C virus genotypes 1 has been shown to be safe and effective, even in the presence of cirrhosis. The combination Sofosbuvir/Ledipasvir is a good option for genotype 2 non-cirrhotic patients.

Copyright © 2021. Published by Elsevier Ltd.